Resotran (REH-zo-tran), a new GI motility agent for chronic constipation

March 2012

Women will be trying Resotran (REH-zo-tran), a new GI motility agent for chronic constipation.

Think of it as a safer version of cisapride (Prepulsid) or tegaserod (Zelnorm). These were taken off the market due to cardiac toxicity.

Resotran (prucalopride) is more selective for 5-HT4 serotonin receptors in the GI tract that stimulate motility.

Get concise advice on drug therapy, plus unlimited access to CE

Pharmacist's Letter Canada includes:

12 issues every year, with brief articles about new meds and hot topics
300+ CE courses, including the popular CE-in-the-Letter
Quick reference drug comparison charts
Access to the entire archive

Subscription Options

Already a subscriber? Log in

Volume pricing available. Get quote

Table of Contents

Cardiology new debate about which anticoagulant is best to prevent strokes in patients with atrial fibrillation
Gastroenterology new warnings that PPIs (omeprazole, etc) might increase the risk of Clostridium difficile-associated diarrhea
Gastroenterology Resotran (REH-zo-tran), a new GI motility agent for chronic constipation
Infectious Diseases higher doses of cephalosporins for treating gonococcal infections
Women's Health whether it's okay for women with migraine headaches to use combined oral contraceptives
Vaccines more MALES get HPV (human papillomavirus) vaccine
Dermatology Many OTCs for bruises and scars don't work
Antithrombotics whether it's okay to use aspirin to prevent thrombosis after hip or knee replacement surgery
Opioids how to handle tramadol drug interaction alerts
Practice if their meds contain animal products
Neurology & Pain You'll get questions about what works for essential tremor